ARROWHEAD PHARMACEUTICALS, INC. Interest Expense
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Interest Expense of $7.24 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-09
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $7.24M, a 43.25% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $5.37M, a 88.38% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $5.26M.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $5.16M.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $18.33M.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $7.24M 10-Q · filed 2024-05-09 | $12.61M 10-Q · filed 2024-05-09 | $17.87M derived: sum of 3 quarters · filed 2024-05-09 | $23.03M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $5.37M 10-Q · filed 2024-02-06 | $10.63M derived: sum of 2 quarters · filed 2024-02-06 | $15.79M derived: sum of 3 quarters · filed 2024-02-06 | $20.84M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-09-30 | $5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $10.42M derived: sum of 2 quarters · filed 2023-11-29 | $15.48M derived: sum of 3 quarters · filed 2024-05-09 | $18.33M 10-K · filed 2023-11-29 |
| 2023-06-30 | $5.16M 10-Q · filed 2023-08-07 | $10.21M derived: sum of 2 quarters · filed 2024-05-09 | $13.06M 10-Q · filed 2023-08-07 | $13.06M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $5.06M 10-Q · filed 2024-05-09 | $7.91M 10-Q · filed 2024-05-09 | $7.91M derived: sum of 3 quarters · filed 2024-05-09 | $7.91M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.85M 10-Q · filed 2024-02-06 | $2.85M derived: sum of 2 quarters · filed 2024-02-06 | $2.85M derived: sum of 3 quarters · filed 2024-02-06 | $2.85M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $0.00 derived: sum of 2 quarters · filed 2023-11-29 | $0.00 derived: sum of 3 quarters · filed 2023-11-29 | $0.00 10-K · filed 2023-11-29 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 2 quarters · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | $0.00 10-Q · filed 2023-05-02 | ||
| 2021-09-30 | $0.00 10-K · filed 2023-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |